Markets

Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%

Galena Biopharma, Inc.GALE was a big mover last session, as its shares rose over 19% on the day. The stock rallied after the FDA granted a Fast Track designation to the company's breast cancer drug, NeuVax. This also led to far more shares changing hands than in a normal session. Yesterday's rally continues the uptrend for the company, as the stock is now up 60% in the past one-month time frame.

Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.

Galena Biopharma currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

A better-ranked biomedical stock is HESKA CORP HSKA , sporting a Zacks Rank #1 (Strong Buy).

Is GALE going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HESKA CORP (HSKA): Free Stock Analysis Report

GALENA BIOPHARM (GALE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HSKA

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More